26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies

Key Takeaways Explain This Topic AI

Validated suicide risk stratification relies on the Columbia-Suicide Severity Rating Scale (C-SSRS) and SAFE-T framework to distinguish passive suicidal ideation from active suicidal intent with a specific plan and accessible lethal means; a history of prior suicide attempt is the single strongest clinical predictor of completed suicide.

Lethal means counseling—specifically inquiring about and restricting access to household firearms and toxic medications—is the single most effective clinical intervention for suicide prevention in primary and urgent care; collaborative Stanley-Brown Safety Planning (a 6-step hierarchical protocol) is evidence-based, whereas traditional 'no-suicide contracts' are clinically ineffective, provide a false sense of security, lack legal validity, and are strictly contraindicated.

Involuntary psychiatric hold criteria require establishing an acute psychiatric disorder resulting in imminent danger to self (suicidality), danger to others (homicidality), or grave disability (inability to satisfy basic survival needs for food, clothing, or shelter); high-risk patients must never be left unmonitored and require continuous 1:1 visual observation in a room stripped of ligature points and dangerous objects.

Acute psychomotor agitation mandates non-coercive verbal de-escalation first-line (BETA framework); if pharmacotherapy is required, oral atypicals plus lorazepam are preferred, whereas violent emergencies require the 'B52' protocol (haloperidol 5 mg + lorazepam 2 mg + diphenhydramine 50 mg IM; diphenhydramine prevents acute extrapyramidal dystonic reactions) or ketamine 4-5 mg/kg IM for severe excited delirium. Intramuscular olanzapine must NEVER be co-administered with parenteral benzodiazepines due to documented risks of fatal cardiorespiratory arrest and severe hypotension.

Hunter Toxicity Criteria for Serotonin Syndrome (spontaneous clonus, tremor, hyperreflexia, hyperthermia; managed with cyproheptadine and benzodiazepines) definitively differentiates it from Neuroleptic Malignant Syndrome (lead-pipe generalized rigidity, hyperthermia, extreme CK elevation >10,000 U/L; managed with dantrolene, bromocriptine, and dopamine agonists).

Last updated: September 2026

Acute Suicide Risk Stratification & Clinical Evaluation

Suicide represents a leading cause of preventable mortality worldwide, accounting for nearly 50,000 deaths annually in the United States alone. Primary care and urgent care clinicians occupy a critical diagnostic frontline: studies demonstrate that approximately 45% of individuals who die by suicide visit a primary care physician in the month preceding their death, and up to 20% do so in the preceding 24 to 48 hours. Rapid, systematic risk stratification, decisive environmental control, and lethal means restriction are vital, life-saving clinical competencies tested rigorously on the ABFM certification examination.

Static versus Dynamic Risk Factors

Clinical risk stratification begins by distinguishing immutable demographic and historical vulnerabilities from modifiable, acute precipitants:

Static (Fixed) Risk Factors :

Prior Suicide Attempt : The single most powerful clinical predictor of future completed suicide. Patients with a prior attempt carry a 30- to 40-fold higher lifetime risk compared to the general population.

Demographics : Male sex (men complete suicide at nearly 4 times the rate of women, primarily due to higher-lethality methods such as firearms; women exhibit higher rates of suicide attempts); older age (men aged ≥75 years exhibit the highest demographic suicide rate); sexual and gender minority status (LGBTQ+ youth experience elevated risk secondary to minority stress and social alienation).

Family History & Genetics : First-degree family history of completed suicide, familial mood disorders, and early childhood physical or sexual abuse.

Chronic Debilitating Medical Illness : Chronic intractable pain syndromes, terminal malignancies, neurodegenerative disorders (e.g., ALS, Huntington disease, Parkinson disease), and severe traumatic brain injury.

Dynamic (Modifiable / Acute) Risk Factors :

Severe Psychic Anxiety, Agitation, and Insomnia : Acute severe psychic pain, akathisia, and intractable insomnia represent immediate short-term red flags for imminent suicidal behavior within 24 to 72 hours.

Substance Intoxication & Substance Use Disorders : Acute alcohol or illicit drug intoxication drastically lowers impulse control, impairs cognitive flexibility, and increases lethal behavioral action.

Acute Relational or Financial Crises : Sudden divorce, romantic rejection, arrest, bankruptcy, or acute bereavement.

Profound Hopelessness & Perceived Burdensomeness : The psychological conviction that one is a burden to loved ones and that future suffering is inescapable.

Active Psychotic Symptoms : Command auditory hallucinations instructing self-harm, or severe persecutory delusions where self-harm is perceived as the only escape.

Validated Risk Stratification Tools: C-SSRS and SAFE-T

Subjective clinical intuition alone is notoriously unreliable for predicting suicide. Guidelines from the American Academy of Family Physicians (AAFP) and The Joint Commission mandate the implementation of standardized, evidence-based screening instruments:

Columbia-Suicide Severity Rating Scale (C-SSRS) :

The C-SSRS systematically deconstructs suicidal thinking across a hierarchical 6-item progression, establishing clinical severity and immediate disposition:

Item 1 (Passive Ideation) : Wish to be dead ("Have you wished you were dead or wished you could go to sleep and not wake up?").

Item 2 (Active Ideation) : General non-specific suicidal thoughts ("Have you actually had any thoughts of killing yourself?").

Item 3 (Active Ideation with Method) : Suicidal thoughts with potential methods without a specific plan ("Have you been thinking about how you might do this?").

Item 4 (Active Ideation with Intent) : Suicidal thoughts with intent to act, but no specific plan ("Have you had these thoughts and had some intention of acting on them?").

Item 5 (Active Ideation with Specific Plan and Intent) : Suicide thoughts with an explicit plan and intent ("Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan?").

Item 6 (Preparatory Behavior) : Engaging in preparatory acts (e.g., collecting pills, buying a firearm, writing a suicide note, giving away possessions, or rehearsing the act).

SAFE-T Framework (Suicide Assessment Five-Step Evaluation and Triage) :

Step 1: Identify Risk Factors (prior attempts, mood disorders, substance abuse, acute stressors).

Step 2: Identify Protective Factors (internal: coping skills, religious/spiritual beliefs against suicide; external: responsibility to dependent children/pets, strong therapeutic rapport, robust social support).

Step 3: Conduct Specific Suicide Inquiry (explore ideation nature, frequency, duration, plan specificity, intent, lethality, and access to means).

Step 4: Determine Risk Level and Choose Intervention (High, Moderate, Low).

Step 5: Document Triage, Rationale, and Follow-Up Safety Plan .

Suicide Risk Stratification Matrix

Risk Category Clinical Profile & C-SSRS Findings Required Immediate Clinical Action Recommended Disposition

High Risk (Imminent) Active suicidal ideation with explicit intent, specific plan, preparatory behavior (C-SSRS 4-6), or accessible lethal means; acute psychosis with command hallucinations; severe agitation/hopelessness; prior high-lethality attempt Continuous 1:1 visual observation ; immediate environmental security sweep; emergency involuntary or voluntary psychiatric admission ; do NOT leave patient unattended Immediate transfer to emergency psychiatric facility via secure Emergency Medical Services (EMS)

Moderate Risk Multiple static risk factors with active suicidal ideation with method or intent, but no specific plan and no immediate intent (C-SSRS 2-3); presence of protective factors; willing to collaborate on safety plan Collaborative lethal means removal; construct formal Stanley-Brown Safety Plan ; involve family/support persons; expedited psychiatric referral; confirmed follow-up appointment within 24 to 48 hours Outpatient management if lethal means removed and reliable social support present; otherwise short-term crisis stabilization

Low Risk Passive suicidal ideation ("wish I were dead") without method, intent, or plan (C-SSRS 1); strong protective factors; mild depressive symptoms; denies prior attempts Construct brief safety plan; provide crisis contacts ( 988 Suicide & Crisis Lifeline ); optimize primary care treatment of underlying depression/anxiety; follow-up within 1 to 2 weeks Outpatient primary care management with behavioral health integration

• Lethal Means Counseling & The Stanley-Brown Safety Plan
• Lethal Means Counseling: The Core Life-Saving Intervention

Suicidal crises are characteristically acute, impulsive, and time-limited: empirical psychological autopsies demonstrate that the interval between the decision to act and the actual suicide attempt is frequently less than 10 to 60 minutes . If lethal means are readily accessible during this acute cognitive constriction, fatal outcomes surge dramatically. Conversely, restricting access to lethal means saves lives—individuals forced to delay an attempt or substitute less lethal methods rarely substitute equally lethal alternatives.

Firearms : The paramount target of lethal means counseling. Firearms account for over 50% of all completed suicides in the United States , boasting a case fatality rate exceeding 85% to 90% (compared to <2% for drug overdoses). Family physicians must routinely and directly ask: "Are there any firearms or guns in your home or accessible to you?"

Intervention : Counsel that during times of emotional crisis, firearms must be removed from the home entirely (transferred to a licensed firearm dealer, secure storage facility, or trusted off-site relative outside the household, in accordance with state gun laws). If temporary off-site removal is refused, mandate that firearms be stored unloaded, locked in a secure gun safe or with cable locks , with ammunition locked in a separate container and keys/combinations entrusted to a third party.

Medication Restriction : Remove large supplies of prescription and over-the-counter medications (e.g., acetaminophen, tricyclic antidepressants, opioids, sedative-hypnotics). Prescribe medications in limited 7-day supplies with blister packs, and entrust medication administration to a reliable family member.

The Stanley-Brown Safety Planning Intervention (SPI)

The Stanley-Brown Safety Plan is an evidence-based, collaborative clinical intervention that empowers patients during emergent suicidal crises. It consists of six hierarchical steps written in the patient's own words:

Step 1: Warning Signs : Personal idiosyncratic thoughts, images, moods, or behavioral changes that signal a developing crisis (e.g., "isolating in my bedroom," "drinking alcohol alone at night," "feeling like a total failure" ).

Step 2: Internal Coping Strategies : Actions the patient can take independently to distract themselves without contacting another person (e.g., "going for a brisk 20-minute run," "listening to instrumental music," "practicing 4-7-8 deep diaphragmatic breathing" ).

Step 3: People and Social Settings that Provide Distraction : Healthy social environments and trusted acquaintances who can provide distraction without discussing the crisis (e.g., "calling my sister to talk about her children," "going to a busy coffee shop or public library" ).

Step 4: People Whom I Can Ask for Help : Trusted family members or close friends who can be openly confided in during an acute crisis (names and direct phone numbers).

Step 5: Professionals and Agencies to Contact : Specific healthcare professionals, local emergency departments, urgent care crisis centers, and national crisis lines: The 988 Suicide & Crisis Lifeline (call or text 988; 24/7/365 free, confidential support) and the Crisis Text Line (text HOME to 741741).

Step 6: Making the Environment Safe : Concrete, verified steps to restrict lethal means (e.g., "my spouse has locked all firearms in the basement safe and holds the only key," "my mother dispenses my medications daily" ).

The Fallacy and Danger of 'No-Suicide Contracts'

Clinical Contraindication : Formal medical guidelines (AAFP, American Psychiatric Association [APA]) explicitly condemn the use of 'no-suicide contracts' (agreements where a patient signs a paper promising not to harm themselves).

Why Contracts Fail :

Zero Empirical Efficacy : No clinical trial has ever demonstrated that no-suicide contracts reduce suicide attempts or completed suicides.

False Sense of Security : Clinicians frequently experience an illusory sense of safety, leading to inappropriate discharge of high-risk patients.

Coercive and Destructive : Contracts can feel coercive, alienating patients and discouraging them from honestly reporting returning suicidal impulses.

Zero Legal Protection : A no-suicide contract carries zero legal weight in malpractice litigation and does not protect a physician against liability for failing to perform an adequate risk assessment.

Involuntary Psychiatric Hold & Emergency Custody Protocols

When a patient is determined to be at imminent risk of suicide or severe harm but refuses voluntary evaluation or attempts to leave the clinical facility, clinicians must execute an Emergency Involuntary Psychiatric Hold (e.g., '5150' in California, 'Baker Act' in Florida, or state-specific equivalents).

Statutory Criteria : The clinician must establish that due to a suspected or diagnosed mental disorder, the patient presents an:

• Imminent Danger to Self (active suicidal intent or life-threatening self-harm);
• Imminent Danger to Others (active homicidal intent or violent assaultive threats);

Grave Disability (inability to provide for basic survival needs: food, clothing, or shelter, placing life in immediate jeopardy).

Facility Management While Awaiting Transport :

Place the patient under continuous 1:1 visual observation (unbroken direct line of sight within arm's length by trained staff).

Secure the physical environment: remove all ligature points, electrical cords, call bells, bed linens, sharp objects, heavy medical equipment, and plastic trash can liners.

Ensure secure transport via Emergency Medical Services (EMS) or law enforcement—never allow family members to transport an actively suicidal patient in a private vehicle.

Acute Agitation: De-Escalation & Emergency Pharmacotherapy

Acute psychomotor agitation is characterized by excessive motor activity, heightened autonomic arousal, severe psychic tension, and verbal or physical aggression. It represents an emergency that threatens the safety of the patient, medical staff, and other patients.

Project BETA Verbal De-Escalation Framework

The American Association for Emergency Psychiatry's Project BETA (Behavioral Emergencies Communication and Assessment) establishes non-coercive verbal de-escalation as the mandatory first-line intervention prior to any pharmacologic or physical restraint:

Maintain Safety & Space : Maintain at least two arm-lengths of distance between yourself and the patient. Never corner the patient, and never allow the patient to block your unobstructed exit route.

Non-Provocative Body Language : Keep hands visible and unclenched; maintain an open, relaxed posture at a 45-degree angle rather than squaring off face-to-face; avoid prolonged intense eye contact.

Establish Verbal Contact : Designate a single clinician as the primary communicator to avoid sensory overload.

Concise, Repetitive Language : Agitated brains exhibit impaired executive processing; speak in short, simple, concrete sentences using a calm, soothing, monotone voice.

Identify Wants and Feelings : Validate emotional distress ( "I can see that you are extremely upset, and I want to help you feel safe here" ) without validating false delusions.

Listen Actively : Paraphrase the patient's words to demonstrate comprehension.

Agree or Agree to Disagree : Find common ground ( "I agree that you shouldn't have had to wait so long to see a doctor" ).

Set Clear, Respectful Limits : Explicitly state behavioral expectations without being punitive ( "I want to help you, but you cannot throw chairs or scream at the nurses" ).

Offer Choices and Optimism : Offer small, empowering choices (e.g., "Would you prefer to sit in the recliner or the bed?" "Can I get you a glass of water or a warm blanket?" ).

Offer Medication Collaboratively : Frame pharmacotherapy as an aid to alleviate overwhelming distress ( "We have medication that can help calm this terrible anxiety and help you feel more in control; would you like to take a pill or a liquid?" ).

Pharmacologic De-Escalation: Oral vs. Parenteral Pathways

When verbal de-escalation proves insufficient and the patient poses an imminent physical threat to self or others, emergency pharmacotherapy is indicated. The clinical goal is rapid calming without inducing deep sedation or unresponsiveness . ACUTE AGITATION PHARMACOTHERAPY ALGORITHM

• Patient Agitated
• │
• ▼
• Project BETA Verbal De-escalation First-Line
• │
• ┌─────────────────────────┴─────────────────────────┐
• ▼ ▼
• Cooperative Patient Combative / Violent / Refusing Oral
• (Oral Formulation Preferred) (Parenteral IM Formulation)
• │ │
• ▼ ▼

Oral Atypical Antipsychotic + Benzodiazepine SELECT REGIMEN:

• Olanzapine 5-10 mg ODT OR 1. "B52" Protocol (Classic Standard):

• Risperidone 1-2 mg ODT OR • Haloperidol 5 mg IM +
• Lorazepam 1-2 mg PO • Lorazepam 2 mg IM +
• Diphenhydramine 50 mg IM (Prevents EPS!)

2. Second-Generation Antipsychotic IM Monotherapy:

• Olanzapine 5-10 mg IM OR
• Ziprasidone 10-20 mg IM

3. Severe Excited Delirium / Hyperactive State:

• Ketamine 4-5 mg/kg IM
• │
• ▼

CRITICAL SAFETY CONTRAINDICATION:

• NEVER co-administer IM Olanzapine with
• parenteral Benzodiazepines (Fatal Arrest!)
• The 'B52' Protocol & Extrapyramidal Prophylaxis

Components : Haloperidol 5 mg IM + Lorazepam 2 mg IM + Diphenhydramine 50 mg IM (frequently drawn into a single syringe or injected simultaneously).

Mechanism & Synergy :

Haloperidol (high-potency typical antipsychotic) provides rapid D2 receptor antagonism to control agitation, psychosis, and mania.

Lorazepam (intermediate-acting benzodiazepine) provides GABAA agonism, producing rapid sedation, anxiolysis, and blunting haloperidol's pro-arrhythmic potential.

Diphenhydramine (anticholinergic/antihistamine) is essential : it blocks striatal muscarinic receptors to counteract the acute dopamine-acetylcholine imbalance caused by high-potency haloperidol, preventing acute extrapyramidal symptoms (EPS), specifically acute dystonic reactions (e.g., torticollis, oculogyric crisis, laryngospasm, opisthotonos).

Atypical Antipsychotic IM Monotherapy & Fatal Drug-Drug Interaction

Intramuscular Second-Generation Antipsychotics :

Olanzapine 5 to 10 mg IM (onset 15-30 minutes); or

Ziprasidone 10 to 20 mg IM (onset 15-30 minutes; max 40 mg/day).

THE CRITICAL BLACK BOX CONTRAINDICATION :

NEVER CO-ADMINISTER INTRAMUSCULAR OLANZAPINE WITH PARENTERAL BENZODIAZEPINES (intramuscular or intravenous lorazepam, diazepam, midazolam).

Co-administration induces synergistic, catastrophic central nervous system depression, profound hypotension, respiratory arrest, and sudden cardiovascular collapse . Clinical practice guidelines require maintaining a minimum separation window of at least 1 to 2 hours between parenteral doses of olanzapine and benzodiazepines.

Ketamine for Excited Delirium & Extreme Combative Agitation

In cases of profound, life-threatening hyperactive delirium with violent combative behavior (excited delirium syndrome / severe sympathomimetic toxicity where traditional neuroleptics are slow or ineffective), Ketamine is the agent of choice.

Dosing : 4 to 5 mg/kg IM (or 1 to 2 mg/kg IV).

Advantages : NMDA receptor antagonism achieves complete dissociative calming within 2 to 5 minutes , rapidly halting dangerous physical exertion, hyperthermia, and metabolic acidosis without compromising spontaneous respiratory drive.

Precautions : Monitor airway closely; risk of emergence reactions, hypersalivation, and laryngospasm (rare).

Serotonin Syndrome vs. Neuroleptic Malignant Syndrome

Both Serotonin Syndrome (SS) and Neuroleptic Malignant Syndrome (NMS) represent life-threatening hyperthermic drug toxicities presenting with altered mental status and autonomic instability. Dissecting their distinct pathophysiologies, clinical presentations, and antidotes is an essential ABFM board skill.

Master Differential: SS versus NMS

Clinical Domain Serotonin Syndrome (SS) Neuroleptic Malignant Syndrome (NMS)

Primary Pathophysiology Excessive intrasynaptic serotonin (5-HT1A, 5-HT2A) receptor stimulation in CNS and peripheral nervous system Severe central dopamine (D2) receptor blockade in basal ganglia and hypothalamus; or abrupt withdrawal of dopamine agonists

Precipitating Medications SSRIs, SNRIs, TCAs, MAOIs, Triptans, Tramadol, Dextromethorphan, Linezolid, MDMA (Ecstasy), St. John's wort Typical (Haloperidol, Fluphenazine) and atypical antipsychotics; Antiemetics (Metoclopramide, Promethazine); abrupt cessation of Levodopa/Carbidopa

Onset Timeline Hyperacute: Minutes to hours (typically <12-24 hours) following dose initiation or drug interaction Subacute: Days to weeks (typically 3-14 days) of therapy; insidious onset

Neuromuscular Hallmarks Neuromuscular Hyperactivity : Spontaneous, inducible, or ocular clonus ; marked hyperreflexia (lower > upper extremities); tremor; shivering Neuromuscular Rigidity : Generalized 'lead-pipe' muscle rigidity ; hyporeflexia or normal reflexes; cogwheeling; flat, parkinsonian posture

Body Temperature Hyperthermia (typically mild to moderate: 38-39°C; >40°C in severe cases) Extreme Hyperthermia (characteristically >40°C [104°F]) due to sustained muscular rigidity

Gastrointestinal Symptoms Prominent : Nausea, vomiting, hyperactive bowel sounds, profuse watery diarrhea Absent or minimal; normal or hypoactive bowel sounds

Key Laboratory Markers Non-specific; mild leukocytosis, mild CK elevation; normal or slightly elevated transaminases Extreme Creatine Kinase (CK) elevation (>10,000 to >100,000 U/L) from severe rhabdomyolysis; marked leukocytosis (10,000-40,000/µL); metabolic acidosis; AKI

Diagnostic Criteria Hunter Toxicity Criteria (requires serotonergic agent + clonus/hyperreflexia) DSM-5 Criteria (neuroleptic exposure + severe rigidity + fever + ≥2 autonomic/laboratory signs)

Specific Medical Antidote Cyproheptadine (oral/NG 5-HT2A serotonin receptor antagonist; initial 12 mg, then 2 mg q2h until response) Dantrolene (direct ryanodine Ca2+ release inhibitor) and/or Bromocriptine / Amantadine (dopamine agonists)

Hunter Toxicity Criteria for Serotonin Syndrome

To establish a diagnosis of Serotonin Syndrome, the patient must have been exposed to a serotonergic agent within the past 5 weeks AND demonstrate at least one of the following:

• Spontaneous clonus ;
• Inducible clonus PLUS either agitation or diaphoresis ;
• Ocular clonus PLUS either agitation or diaphoresis ;
• Tremor PLUS hyperreflexia ;

Hypertonia PLUS temperature >38°C PLUS either ocular clonus or inducible clonus .

Critical Clinical Pearl : Clonus (spontaneous, inducible, or ocular) is the single most specific and sensitive clinical physical examination sign distinguishing Serotonin Syndrome from Neuroleptic Malignant Syndrome.

Loading diagram... Emergency Behavioral & Toxic-Metabolic Agitation Triage Protocol